Table 3 |
|||
|
Overall comparison of the frequency of patients with autoimmune diseases |
|||
|
Proportion (%) of patients receiving co-therapies |
|||
|
|
|||
|
Before rituximab |
During rituximab |
After rituximab during follow-upa |
|
|
|
|||
|
Immunosuppressives |
98.1 |
41.2 |
78.6 |
|
Prednisolone |
68.9 |
66.1 |
58.9 |
|
with glucocorticoid bolus therapy |
17.0 |
1.25 |
1.6 |
|
Methylprednisolone |
25.4 |
13.2 |
4.3 |
|
Methotrexate |
22.1 |
6.9 |
8.9 |
|
Cyclophosphamide |
36.2 |
8.15 |
3.2 |
|
Azathioprine |
38.1 |
11.9 |
10.8 |
|
Mycophenolate mofetil |
27.6 |
15.0 |
17.8 |
|
Intravenous Ig |
17.0 |
3.4 |
5.1 |
|
Plasmapheresis |
13.8 |
3.4 |
0.8 |
|
Other immunosuppressives |
16.0 |
5.3 |
5.4 |
|
|
|||
|
Overall comparison of the frequency of patients with autoimmune diseases receiving at least one administration of different types of therapies before, during and after rituximab therapy. Note, that certain immunosuppressive drugs were substantially different between individual diseases and only frequencies above 10% have been considered for this comparison. aFollow-up was as defined and recorded by the investigating physician. |
|||
|
Tony et al. Arthritis Research & Therapy 2011 13:R75 doi:10.1186/ar3337 |
|||
